Novartis AG's newly-approved CAR-T treatment for childhood leukemia, Kymriah (tisagenlecleucel), will be reimbursed based on outcomes under a groundbreaking arrangement between the manufacturer and the Centers for Medicare and Medicaid Services.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?